Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
This updated systematic review and meta-analysis pooled the results of previous clinical trials assessing the effects of pirfenidone and nintedanib on patients with pulmonary fibrosis. Scopus, the Cochrane Library, PubMed, and Web of Science were searched from the inception to April 12, 2025, to ide...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-07-01
|
| Series: | Annals of Thoracic Medicine |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/atm.atm_132_25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394729359245312 |
|---|---|
| author | Yiting Qiu Wei Ye |
| author_facet | Yiting Qiu Wei Ye |
| author_sort | Yiting Qiu |
| collection | DOAJ |
| description | This updated systematic review and meta-analysis pooled the results of previous clinical trials assessing the effects of pirfenidone and nintedanib on patients with pulmonary fibrosis. Scopus, the Cochrane Library, PubMed, and Web of Science were searched from the inception to April 12, 2025, to identify randomized controlled trials measuring the effect of pirfenidone and nintedanib on pulmonary fibrosis. Because of high methodological heterogeneity, we utilized a random-effects model (DerSimonian-Laird) to perform this meta-analysis. Finally, 18 articles with 20 randomized controlled trials were included in this meta-analysis. We found that compared to placebo, treatment with the two antifibrotic drugs increased forced vital capacity (FVC) predicted (weighted mean difference [WMD] 3.12%, 95% confidence interval [CI] [1.41, 4.82], I2 = 53.30%), FVC volume (WMD 87.44 ml, 95% CI [59.32, 115.57], I2 = 99.4%), and the distance walked in the 6-minute walk test (WMD 24.63 m, 95% CI [16.05, 33.22], I2 = 0.00%). However, compared to placebo, treatment with the two antifibrotic drugs did not significantly change the diffusing capacity of the lungs for carbon monoxide (WMD 1.38 ml/min/mmHg, 95% CI [−9.42, 12.18], I2 = 0.00%). Therapeutic benefits were observed for both pirfenidone and nintedanib and for both idiopathic pulmonary fibrosis (IPF) and non-IPF. Pirfenidone and nintedanib can improve lung function and functional capacity in patients with different types of pulmonary fibrosis. |
| format | Article |
| id | doaj-art-eed3344824824b1eb8a7ebecbfdffe4e |
| institution | Kabale University |
| issn | 1817-1737 1998-3557 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Thoracic Medicine |
| spelling | doaj-art-eed3344824824b1eb8a7ebecbfdffe4e2025-08-20T03:39:54ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572025-07-0120314515210.4103/atm.atm_132_25Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysisYiting QiuWei YeThis updated systematic review and meta-analysis pooled the results of previous clinical trials assessing the effects of pirfenidone and nintedanib on patients with pulmonary fibrosis. Scopus, the Cochrane Library, PubMed, and Web of Science were searched from the inception to April 12, 2025, to identify randomized controlled trials measuring the effect of pirfenidone and nintedanib on pulmonary fibrosis. Because of high methodological heterogeneity, we utilized a random-effects model (DerSimonian-Laird) to perform this meta-analysis. Finally, 18 articles with 20 randomized controlled trials were included in this meta-analysis. We found that compared to placebo, treatment with the two antifibrotic drugs increased forced vital capacity (FVC) predicted (weighted mean difference [WMD] 3.12%, 95% confidence interval [CI] [1.41, 4.82], I2 = 53.30%), FVC volume (WMD 87.44 ml, 95% CI [59.32, 115.57], I2 = 99.4%), and the distance walked in the 6-minute walk test (WMD 24.63 m, 95% CI [16.05, 33.22], I2 = 0.00%). However, compared to placebo, treatment with the two antifibrotic drugs did not significantly change the diffusing capacity of the lungs for carbon monoxide (WMD 1.38 ml/min/mmHg, 95% CI [−9.42, 12.18], I2 = 0.00%). Therapeutic benefits were observed for both pirfenidone and nintedanib and for both idiopathic pulmonary fibrosis (IPF) and non-IPF. Pirfenidone and nintedanib can improve lung function and functional capacity in patients with different types of pulmonary fibrosis.https://journals.lww.com/10.4103/atm.atm_132_256-min walk testforced vital capacitymeta-analysisnintedanibpirfenidonepulmonary fibrosis |
| spellingShingle | Yiting Qiu Wei Ye Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis Annals of Thoracic Medicine 6-min walk test forced vital capacity meta-analysis nintedanib pirfenidone pulmonary fibrosis |
| title | Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis |
| title_full | Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis |
| title_fullStr | Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis |
| title_full_unstemmed | Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis |
| title_short | Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis |
| title_sort | therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis a systematic review and meta analysis |
| topic | 6-min walk test forced vital capacity meta-analysis nintedanib pirfenidone pulmonary fibrosis |
| url | https://journals.lww.com/10.4103/atm.atm_132_25 |
| work_keys_str_mv | AT yitingqiu therapeuticefficacyofpirfenidoneandnintedanibinpulmonaryfibrosisasystematicreviewandmetaanalysis AT weiye therapeuticefficacyofpirfenidoneandnintedanibinpulmonaryfibrosisasystematicreviewandmetaanalysis |